Study to Evaluate the Safety, Tolerability, and Efficacy of Cilofexor in Adults With Primary Biliary Cholangitis Without Cirrhosis

Key Inclusion Criteria: * Meets all of the following conditions * Definite or probable PBC as defined by at least 2 of the 3 following criteria: * Serum alkaline phosphatase (ALP) \> the upper limit of normal (ULN) * Presence of anti-mitochondrial antibodies (AMA) in serum (≥ 1:40 on immunofluorescence) * Liver histological findings consistent with PBC including nonsuppurative, destructive cholangitis affecting mainly the interlobular bile and septal bile ducts * Serum ALP \> 1.67 x ULN and/or total bilirubin \>ULN but ≤ 2 x ULN * Ursodeoxycholic acid (UDCA) use at a stable dose for at least 12 months or intolerant of UDCA with no UDCA use for at least 12 months before screening * Screening FibroSURE/FibroTest® \< 0.75 unless a historical liver biopsy within 12 months of screening does not reveal cirrhosis. In adults with Gilbert's syndrome or hemolysis, FibroSURE/FibroTest will be calculated using direct bilirubin instead of total bilirubin. Key Exclusion Criteria: * Alanine aminotransferase (ALT) \> 5 x ULN * Total bilirubin \> 2 x ULN * International normalized ratio (INR) \> 1.2 unless on anticoagulant therapy * Other causes of liver disease including viral, metabolic, alcoholic, and other autoimmune conditions. Participants with hepatic steatosis may be included if there is no evidence of nonalcoholic steatohepatitis (NASH) in the opinion of the investigator or on liver biopsy. * Use of fibrates or obeticholic acid within 3 months prior to screening through the end of treatment * Cirrhosis of the liver as defined by any of the following: * Historical liver biopsy demonstrating cirrhosis (eg, Ludwig stage 4 or Ishak stage ≥ 5) * History of decompensated liver disease, including ascites, hepatic encephalopathy or variceal bleeding * Liver stiffness \> 16.9 kPa by FibroScan® Note: Other protocol defined Inclusion/Exclusion criteria may apply.